In this study, a patient with B-ALL (BCR::ABL/p210+) developed resistance toseveral TKIs (dasatinib, busutinib, and asciminib), as well as topolychemotherapy including the FLAG regimen. This evidence concerns the gene EVPL and acute lymphoblastic leukemia.